Lack of transparency in pharmaceutical data sharing

Mainstream drugs for which raw patient datasets have not been released

Available public reporting shows systemic gaps in sharing individual participant data (IPD) for many commercially developed medicines — for example, roughly half of participant‑level datasets that sup...